YOKOHAMA, Japan--(BUSINESS WIRE)-- Nissan has commenced demonstrations of a prototype vehicle equipped with its in-house-developed, autonomous drive technologies - showcasing progress in its goal towards rolling out autonomous mobility services within fiscal year 2027.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602021801/en/
(Photo: Business Wire)
The Nissan LEAF prototype vehicle incorporates 14... (continue reading...)
LOS ANGELES--(BUSINESS WIRE)-- WEBTOON Entertainment Inc. (“WEBTOON” or “the Company”), a leading global entertainment company and home to some of the world’s largest storytelling platforms, today announced that it publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) on Friday, May 31, 2024, relating to a proposed initial public offering of its common stock.
The number of shares to be offered... (continue reading...)
Exciting New Application from Intel Enables Fast PC-to-PC Connectivity
TAIPEI, Taiwan--(BUSINESS WIRE)-- Other World Computing – the leading solution provider of computer hardware, accessories, and software that bring artistic expression and the digital world together for creative professionals and consumers of technology – today announced at the COMPUTEX tradeshow, a collaboration with Intel® Thunderbolt™ Share to provide fast PC-to-PC experiences via the... (continue reading...)
- ‘Ultra-sensitive’ cancer blood test is highly accurate in identifying which breast cancer patients will relapse
- The ‘Personalis NeXT Personal® liquid biopsy’ test uses whole genome sequencing to identify up to 1,800 mutations in a patient’s tumour DNA that can identify recurrence of the patient’s cancer from a blood sample
- The median lead time from detection of disease to clinical relapse (shown on imaging) was 15 months – over three months... (continue reading...)
First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal... (continue reading...)
More Business Wire
View Older Stories-
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
-
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
-
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
-
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
-
June Joy at Juicy Stakes Casino
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Generation Mining Files Final Base Shelf Prospectus and Updates Shareholders
-
Tikehau Capital: Disclosure of shares repurchases from 24 May 2024 to 30 May 2024
-
Government Regulation Creates Blue Oceans
-
Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
-
Leading Independent Proxy Advisory Firm Institutional Shareholder Services Joins Glass Lewis in Recommending Votes “FOR” ALL Nine WisdomTree Board Nominees
-
BRW Announces Notification of Sources of Distributions
-
SABA Announces Notification of Sources of Distributions
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Che
-
FCPT Announces Acquisition of a Mavis Tire Property for $2.4 Million
-
University of Phoenix and Executive Networks Study on Workplace Well-Being Highlights Challenges of Current Approaches in Addressing Mental Health
-
Capstone Copper Announces Retirement of Robert Gallagher from the Board of Directors
-
Drive Shack Inc. Releases Fourth Quarter and Full-Year 2023 Financial Results
-
Medical Properties Trust Publishes Its Third Annual Corporate Responsibility Report
-
FCPT Announces Acquisition of a National Veterinary Associates Property for $2.0 Million
-
Fonon's Additive Manufacturing Technology To Transform Construction Industry
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Ventas to Present at Nareit’s REITweek 2024 Investor Conference